Additionally, enhanced anti-tumor immunity was seen in a gastric cancer model with combination therapy that blocked Tim-3, LAG-3, and PD-1, indicating the promise of this approach as a treatment [23,24]. The gene discussed is HAVCR2; the disease is gastric cancer.